

## **Cancer Control Program Symptom Intervention Committee**

200 First Street, SW Rochester, MN 55905 P: 507-266-9202 F: 507-284-1803

www.allianceforclinicaltrialsinoncology.org

Charles L. Loprinzi, M.D. Chair

# Agenda Symptom Intervention Committee Meeting Friday November 7, 2014 7:00-9:00 AM CST Room: TBD

Meeting available by teleconference: Dial 800-501-8979 Access Code: 7181781

Committee Leadership Members:		
Charles L. Loprinzi, MD	Chair	cloprinzi@mayo.edu
Deb Barton, RN, PhD	Co-vice Chair	debbartn@med.umich.edu
Andrew L. Himelstein, MD	Co-vice Chair	ahimelstein@cbg.org
Kathryn J. Ruddy, MD	Co-vice Chair	Ruddy.Kathryn@mayo.edu
Ellen L. Smith, PhD	Co-vice Chair	ellenls@med.umich.edu
Jan C. Buckner, MD	CCP Program Director	buckner.jan@mayo.edu
Jacqueline M. Lafky, MS	CCP Program Manager	lafky.jacqueline@mayo.edu

- I. New Concepts
- II. Status of Concepts
- III. Recently Opened Protocols
- IV. Other Open Studies
- V. Associated Pilot Trials
- VI. Studies Recently Closed, Being Analyzed
- VII. Abstracts Since May 2014
- VIII. Publications Since May 2014
- IX. Other Business

#### Symptom Intervention Publications since May 2014

### Primary Sponsoring Committee Manuscripts

- Barton, D. L., G. Thanarajasingam, et al. (2014). "Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance)." Cancer. PMID: 25043153. (Epub ahead of print 2014 Jul 9)
- Leal, A. D., R. Qin, et al. (2014). "North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study." <a href="Mailto:Cancer">Cancer</a> 120(12): 1890-1897. PMID: 24619793. (2014 Jun 15)
- Leenstra, J. L., R. C. Miller, et al. (2014). "Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Head and Neck Radiotherapy With or Without Chemotherapy: A Phase III, Randomized, Double-Blind Trial (NCCTG-N09C6 [Alliance])." J Clin Oncol **32**(15): 1571-1577. PMID: 24733799. (2014 May 20)
- Park, H., R. Qin, et al. (Accepted 8/27/2014). "NCCTG N10C2 (Alliance) A Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes " Menopause.

#### **Abstracts**

- Barton, D. L., J. A. Sloan, et al. (2014). "Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance)." <u>J Clin Oncol</u> **32**(15\_suppl): 9507. Oral presentation. (2014 Jun 11)
- Barton, D. L., J. A. Sloan, et al. (2014). "Physiologic effects of Vaginal Dehydroepiandosterone (DHEA): Alliance Trial N10C1." <u>Support Care Cancer</u> **22**(Suppl 1): S223; MASCC-0049. Oral presentation. (2014 Jun)
- Barton, D., T. Dockter, et al. (2014). Addressing the complexities of sexual health in cancer survivors. Council for the Advancement of Nursing Science, Washington, DC. September 18-20, 2014. Oral presentation.
- Lustberg, M., T. Orchard, et al. (Accepted SABCS 2014). "Prevention of Aromatase Inhibitor (AI)-induced Joint Symptoms with Omega 3 Fatty Acid Supplementation: A Randomized Placebo-Controlled Pilot Study."
- Miller, R. C., D. G. Petereit, et al. (2014). "Primary and Secondary Endpoint Analysis of N08C9 (Alliance): A Phase 3 Randomized Trial of Sulfasalazine Versus Placebo in the Prevention of Acute Radiation Enteritis." <a href="International Journal of Radiation Oncology\*Biology\*Physics">International Journal of Radiation Oncology\*Biology\*Physics</a> 90(1, Supplement): S86. Oral presentation. (2014 Sep)
- Moukharskaya, J., D. M. Abrams, et al. (2014). "Randomized phase II pilot study of loratadine for the prevention of bone pain caused by pegfilgrastim." <u>J Clin Oncol</u> **32**(15\_suppl): 9628. (CALGB Pilot; NCT01311336) Poster presentation. (2014 Jun 11)
- Orchard, T. S., X. Pan, et al. (Accepted SABCS 2014). "Relationship of dietary and red blood cell (RBC) polyunsaturated fatty acids (PUFAs) to inflammatory markers in breast cancer survivors taking Aromatase Inhibitors (AI)."
- Pachman, D. R., R. Qin, et al. (2014). "Clinical course of patients with oxaliplatin-associated neuropathy: N08CB (Alliance)." <u>J Clin Oncol</u> **32**(15\_suppl): 3595. Poster presentation. (2014 Jun 11)
- Park, H., R. Qin, et al. (2014). "NCCTG N10C2 (Alliance): A double-blind, placebo-controlled study of magnesium supplements to reduce menopausal hot flashes." <u>J Clin Oncol</u> **32**(15\_suppl): 9508. Oral presentation. (2014 Jun 11)